Trupanion Inc

Trupanion Inc(TRUP)股票分析

$28.760

+1.317 (+4.58%)收盤時

Loading chart…
最高
28.810
開盤
27.570
成交量加權均價
28.37
成交量
234.19K
市值
1.25B
最低
27.550
成交金額
6.64M
企業價值/稅息折舊攤銷前利潤(TTM)
26.65

Trupanion, Inc. is a medical insurance provider for cats and dogs throughout the United States, Canada, and certain countries in Continental Europe. The Company operates in two segments, namely, Subscription Business and Other Business. The Subscription Business segment is based on subscription payments related to the Company’s direct-to-consumer products. The Other business segment is focuses on other product offerings, primarily involving the underwriting of policies on behalf of third parties with whom the Company maintains business-to-business relationships. It offers Trupanion, software that is designed to communicate directly with veterinary hospital's practice management software. It provides Powered by Trupanion pet insurance product offerings marketed by third parties and marketed under the brand names Furkin and PHI Direct in Canada, and a Trupanion branded product in Germany and Switzerland.

AI 分析 of Trupanion Inc (TRUP)

持有

Trupanion Inc is currently priced at $28.12, with a high RSI of 91.244 indicating potential overbought conditions. The forward P/E ratio is extremely high at 1428.57, suggesting that the stock may be overvalued compared to its earnings potential. Despite a recent revenue growth of 11% year-over-year in Q2 2026, the stock has seen a significant decline of 36.11% over the past year. The main risk is the downgrade from Piper Sandler, citing a dual-threat macro environment affecting pet insurance demand.

分析師評級(6)

上檔空間 +89.15%
買進
6 買進
0 持有
0 賣出
目前: 28.76
最低
42.00
平均
54.40
最高
63.00

Cantor Fitzgerald

2026-10-07

目標價

$30

中性

Piper Sandler

2026-08-26

目標價

$32

中性

Stifel

2026-08-20

目標價

$29

持有

BofA

2026-07-15

目標價

$42

買進

BofA

2026-05-01

目標價

$52

買進

估值指標

Trupanion Inc(TRUP)目前預期本益比為 1428.57,5 年平均預期本益比為 113.66。

預期本益比

合理
5 年均值 P/E
113.66
目前P/E
1428.57
高估
1722.23
低估
-1494.91

預期 EV/EBITDA

合理
5 年均值 EV/EBITDA
7.45
目前EV/EBITDA
26.65
高估
492.07
低估
-477.18

預期股價營收比

合理
5 年均值 P/S
1.68
目前P/S
0.70
高估
2.94
低估
0.42

Alphio AI 對 TRUP 的價格情境

情境價格取自當年最後一個月度預測區間。機率為固定的模型權重(25 / 50 / 25),不構成保證。

樂

樂觀

樂觀 · 25%TRUP

$54.58

情境價格

基

基準

基準 · 50%TRUP

$45.54

情境價格

悲

悲觀

悲觀 · 25%TRUP

$34.42

情境價格

持有 TRUP 的大戶

C

Check Capital Management Inc

+ 持有TRUP

-1.27%

3個月報酬率

事件時間軸

2026-08-05 (ET)

17:30:00

Trupanion Q2 Revenue $392.93M Beats Expectations

17:30:00

Company Authorizes Share Repurchase Program Up to $100M

2026-04-30 (ET)

16:40:00

Trupanion Reports Q1 Revenue of $384M

2026-03-10 (ET)

09:10:00

Trupanion Partners with HABRI to Strengthen Human-Animal Bond

2026-02-12 (ET)

16:30:00

Trupanion Q4 Revenue $376.9M Exceeds Expectations

資訊

TRUP 常見問題 —— 由 Alphio AI 解答

Trupanion, Inc. is a medical insurance provider for cats and dogs throughout the United States, Canada, and certain countries in Continental Europe. The Company operates in two segments, namely, Subscription Business and Other Business. The Subscription Business segment is based on subscription payments related to the Company’s direct-to-consumer products. The Other business segment is focuses on other product offerings, primarily involving the underwriting of policies on behalf of third parties with whom the Company maintains business-to-business relationships. It offers Trupanion, software that is designed to communicate directly with veterinary hospital's practice management software. It provides Powered by Trupanion pet insurance product offerings marketed by third parties and marketed under the brand names Furkin and PHI Direct in Canada, and a Trupanion branded product in Germany and Switzerland. It operates in the Financials sector (HOSPITAL & MEDICAL SERVICE PLANS industry).

Trupanion Inc is currently priced at $28.12, with a high RSI of 91.244 indicating potential overbought conditions. The forward P/E ratio is extremely high at 1428.57, suggesting that the stock may be overvalued compared to its earnings potential. Despite a recent revenue growth of 11% year-over-year in Q2 2026, the stock has seen a significant decline of 36.11% over the past year. The main risk is the downgrade from Piper Sandler, citing a dual-threat macro environment affecting pet insurance demand.

6 analysts cover TRUP: 6 rate it Buy, 0 Hold and 0 Sell. The average price target is 54.40.

暫無貼文

註冊或登入後參與討論

本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。

開始交易